GOLDEN, COLO / ACCESSWIRE / June 29, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th 2020 financial results of operations.

Vitro Diagnostics Inc. ("Vitro Biopharma") announced a reduction in 2nd quarter revenues across all its revenue categories. Vitro Biopharma recorded 2nd quarter revenues of $128,631 vs $211,900 a decrease of 39% over the same comparative quarter last year. Prior to the lockdowns which began at different times for different jurisdictions Vitro had reported increasing revenues across all its revenue categories for 13 consecutive quarters. We expect to see revenue returning in the 4th quarter of 2020 and into the first half of 2021. Preliminary feedback from our customers indicates that patients awaiting treatments at our partner clinic in the Cayman Islands www.DVCstem.com are not dropping off but merely postponing their treatments and as such a backlog is building rather than customer cancellations. The cosmetic clinics www.Infinivive.com have started to open up but only with reduced occupancy and variations by state and hence reduced revenue into the 3rd quarter with expectations of a revival of revenue in the 4th quarter of 2020 and into the first half of 2021.

Overall operating expenses increased in the quarter by $114,178 to $281,485 from $167,307 in the prior year's comparative quarter. The increase in expenses reflects the increased costs of FDA regulatory, legal, consulting, business and product development expenses. The company added extra resources to turn its attention to the world wide challenge of finding therapies to fight the Covid-19. Vitro filed an Investigational New Drug ("IND") application and also received emergency use authorization from the FDA for use of AlloRx Stem Cells ® in the treatment of COVID-19 patients. A patient was treated subsequent to the end of the second quarter. There were no adverse events demonstrating safety and the patient showed evidence of efficacy including improved lung and kidney function. We also entered into an MOU with GIOSTAR, a leading global stem cell research operating multiple international stem cell clinics.

During and subsequent to the quarter the company achieved and pursed the following objectives:

Series A Convertible Preferred Stock Offering:

During the quarter and subsequent to the quarter the company continued with its Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $550,000 of the Series A Convertible Preferred Stock during and subsequent to the quarter. The offering was sold out at $1,000,000 and the company is considering expanding it to ensure sufficient working capital during the Coronavirus pandemic and to start the regulatory process of current reporting audits and funding for its expanded clinical trial activities with the FDA.

Filed Investigational New Drug (IND) Application with the FDA

As a part of our overall strategy to target both global and US stem cell markets, Vitro submitted a Phase I IND application to the FDA https://vitrobiopharma.com/vitro-biopharma-submits-ind-application-to-fda-for-allorx-stem-cellr-therapy-of-covid-19/) to assess safety of AlloRx Stem Cells® in the treatment of COVID-19 patients in the US. Recent umbilical cord stem cell therapies in China to fight the Coronavirus has produced encouraging safety and efficacy results. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells®. The application is presently under review and we are working closely with FDA reviewers to gain authorization to enroll patients. Several clinical centers have expressed interest in our stem cell therapy. We are also pursuing other avenues for Emergency Use Authorization (EUA). The FDA has thus far authorized three separate EUA applications for compassionate use of AlloRx Stem Cells® in COVID-19 patients. Unfortunately, two patients died prior to treatment. A single patient has been treated by three separate dosages of AlloRx Stem Cells® through an authorized EUA by GIOSTAR. There were no adverse events and the patient who has various comorbidities stabilized and exhibited enhanced pulmonary and renal functions during the six weeks following AlloRx Stem Cell® Therapy. While presently intubated and hospitalized in the ICU, this patient is exhibiting gradual improvement. We are presently pursuing additional EUA applications through our collaboration with GIOSTAR https://vitrobiopharma.com/vitro-biopharma-signs-mou-with-GIOSTAR-for-covid-19-ind-using-allorx-stem-cells/. The data obtained from these studies corroborates our studies of safety and efficacy. Mesenchymal Stem Cells ("MSCs") block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects. The cytokine storm leads to the need for assisted breathing by ventilators, transfer to ICU and tremendous burdens on the US health care system. It is important to note that AlloRx Stem Cells® are therapy for other viral attacks including influenza since stem cells block acute respiratory distress and damage to other major organs including cardiovascular, pulmonary and renal systems. AlloRx Stem Cells® are very likely to assist in recovery from failure of various organ systems in COVID-19 survivors, as our case study is demonstrating.

MOU with GIOSTAR

We entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. ("GIOSTAR") a leading stem cell research institute based in San Diego, California to jointly partner together for a separate COVID-19 Investigational New Drug ("IND") application to the FDA using Vitro Biopharma's umbilical cord MSC product AlloRx Stem Cells™ in a clinical trial to treat Covid-19 patients https://vitrobiopharma.com/vitro-biopharma-signs-mou-with-GIOSTAR-for-covid-19-ind-using-allorx-stem-cells/ GIOSTAR is a worldwide leader in the in the field of stem cell research and has stem cell research and treatment facilities around the world. GIOSTAR is leading the way for filling the joint IND application for a Covid-19 trial with the FDA while Vitro will provide its AlloRx Stem Cells® for use in the study and post-approval stages through a supply agreement with GIOSTAR. GIOSTAR has already obtained EUAs from the FDA for using stem cell treatment for severe Covid-19 hospitalized patients using AlloRx Stem Cells®. https://www.GIOSTAR.com/2020/05/01/GIOSTAR-announces-fda-approval-compassionate-use-treat- covid-19-stem-cells-2/

Vitro will continue to seek FDA authorization of its pending IND. As the approval process proceeds, Vitro will seek AlloRx Stem Cells® FDA approval through Phase 2/3 IND filings for indications other than COVID-19 such as osteoarthritis while at the same time continuing to supply GIOSTAR AlloRx Stem Cells® for treatment of COVID-19 patients in global markets.

GIOSTAR in collaboration with government of Gujarat, India is building one of the world's largest stem cell hospitals. This is a dream project of India's Prime Minister Narendra Modi. The MOU stated the intended discussions regarding the use of AlloRx Stem Cells® at GIOSTAR's various international stem cell facilities that would provide quality and economic advantages.

Continued expansion of our manufacturing capacity

The company is doubling its laboratory and manufacturing facilities and expanding its clean room by 100% in size and capacity. This new facility is expected to be online during the 1st quarter of next year. This represents approximately $6M of AlloRx Stem Cell™ Vitro Biopharma revenue capacity per year. Furthermore, the completion of the 2nd clean room processing facility at the beginning of the 2021 year will expand our capacity to approximately 100 Billion AlloRx Stem Cell™ s a month or approximately $1.7 Million of AlloRx Stem Cell™ Vitro Biopharma revenue capacity per month. This would give Vitro Biopharma a revenue run rate capacity of $20M a year.

Our increased capacity is rigorously controlled by our Quality Management System, now certified to the ISO9001 Quality and the ISO13485 Medical Device Standards as well. This provides GMP-compliant manufacturing of the highest quality stem cells/medical devices for clinical trial testing to provide further evidence of safety and efficacy for treatment of a wide variety of indications. Highly regulated GMP biologics manufacturing within an FDA-compliant facility provides numerous opportunities to the Company to drive strong revenue growth. We are presently focused on our partnerships in the Caribbean with DVC Stem in Grand Cayman Island, Infinivive MD in the US and emerging opportunities in the Commonwealth of the Bahamas. We are actively pursuing other partnership opportunities as well.

STEMulize™ manufacturing update:

We have reformulated with our Contract Manufacture to produce STEMulize™ in large quantity manufacturing runs. STEMulize™ contains natural substances that activate the body's own stem cells to enhance recovery from injury such as TBI, stroke, MS, PD and other autoimmune, inflammatory and neurological diseases. The STEMulize™ product will be offered as a private label product to Infinivive MD™ clinics and is being implemented as supplemental support to clinical treatments now ongoing in the Cayman Islands. Patients report positive benefits from STEMulize™ therapy following stem cell transplants including increased overall energy and enhancement of improved motor function in MS patients. We are currently pursing licensing arrangements with nutraceutical companies that can scale our formulation under their own private label.

Reduced Revenue from Infinivive MD™ Serum due to closure of the cosmetic clinics

The Company's cosmetic stem cell serum private labelled as Infinivive MD Serum is being applied as a topical cosmetic serum in medical spas and plastic surgery offices. Infinivive MD™ revenue was reduced by the Coronavirus pandemic and as a result, revenues declined by 50% in the quarter to approximately $50,000 vs $100,000 in the prior quarter. This also compares to $50,000 in the current quarter of 2020 vs $130,000 in the prior comparative quarter of 2019.

The Joint Development and Supply Agreement dated May 15th 2018 between Vitro Biopharma and Jack Zamora is being renegotiated due to the Coronavirus pandemic and as such the minimum exclusivity requirements have been delayed by approximately a year.

Infinivive MD™ Cosmetic Serum is revolutionizing the cosmetic industry. Patients are experiencing unparalleled improvements in the appearance of fine lines and wrinkles. This is one of the fastest growing revenue streams for Vitro Biopharma. We work with a variety of regulatory experts to assist us in the appropriate regulatory pathway. At this point it is regulated as a cosmetic topical product but may be reclassified based on regulatory input.

www.jackzamoramd.com www.infinivivemd.com

Infinivive MD™ also has an exclusive agreement to distribute AlloRx Stem Cells™ into the countries of Saudi Arabia, U.A.E., and Colombia. A trial was conducted in Kuwait prior to the pandemic and upon reopening of the country the first commercial orders will be shipped. The agreement calls for minimum commitments to maintain exclusivity and provides for minimum revenue of $250,000 annually in 2020. However due to the worldwide Corona Virus lockdown of business and customers the agreement for performance requirements have been delayed by approximately a year.

Vitro Biopharma's OEM cosmetic topical serum is being distributed exclusively by Infinivive MD™ into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in a number of clinics throughout the United States and soon internationally; but with the clinics just opening again for business and with limited occupancy rules we do not expect this revenue to recover back to peak levels with growth until the first half of 2021.

Update on the Clinical Trial of Musculoskeletal Conditions in the Bahamas

This initiative broadens Vitro Biopharma's expansion into highly regulated stem cell trials in collaboration with the Nassau-based Medical Pavilion of the Bahamas (TMPB).

http://www.tmp-bahamas.com

We will now be able to extend stem cell therapy based on our novel, patent-pending AlloRx Stem Cell™ product to a variety of musculoskeletal conditions. These include OA of any joint, ACL/MCL tear, Achilles tendon rupture, rotator cuff injury, tennis elbow and herniated disc that are highly prevalent and have few disease-modifying options. It is important to note that many stem cell treatments now performed are problematic due to limited potency and failure to meet basic qualification criteria of MSC stem cells.. Also, contamination due to poor production methods that are not in compliance with FDA regulations has caused serious complications, resulting in FDA warning letters due to manufacturing infractions. Vitro Biopharma operates a highly regulated, FDA-compliant commercial biologics manufacturing operation for several years and is cGMP compliant, ISO 9001 Certified, ISO 13485 Certified, CLIA Certified and FDA registered. All manufacturing occurs in a certified sterile clean room with extensive and advanced testing to assure the absence of contamination. Furthermore, in numerous patients treated to date by IV infusion of AlloRx Stem Cells™ there have been no significant adverse events.''

The company is partnered with Dr. Conville Brown, MD, MBBS, FACC, FESC, PhD, the founder and CEO of the Medical Pavilion of the Bahamas who is the Principal Investigator of this trial and director of its clinical administration. Dr Brown was instrumental in the establishment of the National Stem Cell Ethics Committee in the Bahamas.

About the Medical Pavilion of the Bahamas: TMPB operates within a 40,000 square foot building as a partnered care specialty medical facility with 10 different centers in various areas including cardiology, cancer, clinical research and kidney disease. One of the centers is the Partners Stem Cell Centre, where the present trial will be conducted. The Partners Stem Cell Centre provides an environment to conduct stem cell research and clinical trials under the model of ''FDA rigor in a Non-FDA Jurisdiction'' TMPB employs 20 medical specialists in various fields. See www.tmp-bahamas.com for additional information.

The company expects to begin patient enrollment for the clinical trial in late QIV but does not expect to realize revenue until QI/QII of 2021.

Temporary hold on revenues from the clinical trials in the Cayman Islands:

Due to the Corona virus pandemic the Cayman Islands closed itself and its businesses down for the majority of the quarter and next quarter, the current status is listed as locked down until Sept. 1st 2020. However, our partner reports that customers are staying on the waiting list and will return for their treatments as soon as the island opens back up. There currently is a backlog of patients of over 40 treatments pending which exceeds all of the treatments performed in 2019. We expect to see a surge in revenues from this backlog to bring back our revenue stream in the fourth quarter of 2020 and into the first half of 2021.

Expanded our Patent & Intellectual Property Portfolio

The Company has several patent applications (11) pending in the US and foreign jurisdictions. These patents cover our AlloRx Stem Cell™ line and various aspects of our STEMulize™ stem cell activation products & processes as well as specific diagnostic tests of stem cell activity and therapeutic effectiveness. During the quarter, the Company has responded to office actions and continues to vigorously prosecute & expand its patent filings.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are pleased to report our activities in fighting the Covid-19 with filings of our eIND and INDs and partnership with GIOSTAR. While we are disappointed in the extraordinary impact of the Corona Virus pandemic and its results on our operations, we have taken the time to advance our clinical applications and partnerships in further preparation for realized growth in 2021 as a result of these activities.

Our stem cell products are distinctly superior to stem cell transplants in the USA. The latter usually involve use of impure products lacking validation as stem cells and containing insufficient numbers of stem cells to achieve therapeutic benefits. These are produced without regulatory oversight and have been known to cause serious adverse effects. Hence the use of highly purified and well characterized stem cells (AlloRx Stem Cells™) is needed to provide safety and efficacy in regenerative medicine therapies.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10+ years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We plan to leverage our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Vitro Biopharma has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with its Umbilical Cord Mesenchymal Stem Cells (AlloRx Stem Cells™), and it's MSC-Grow™ Brand of cell culture media along with advanced stem cell diagnostic services. www.vitrobiopharma.com

Sincerely yours,

James R. Musick, PhD.
President, CEO & Chairman of the Board
www.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward- looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro BioPharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com
www.vitrobiopharma.com

Vitro Diagnostics, Inc.

Quarter Ended April 30th;

 
2020
 
 
2019
 

Income Statement

Stem Cell Therapies and Treatments

 
 
82,050
 
 
 
163,858
 

Stem Cell Products

 
 
43,288
 
 
 
46,160
 

Other Services

 
 
3,293
 
 
 
1,882
 

Total Revenues

 
 
128,631
 
 
 
211,900
 

COGS

 
 
46,727
 
 
 
56,998
 

Gross Profit

 
 
81,904 
64%
 
 
154,902 
73%

SGA Expenses

 
 
79,351
 
 
 
55,443
 

Office Expenses

 
 
9,443
 
 
 
8,813
 

Consulting,Accounting,Legal and Banking Fees

 
 
127,304
 
 
 
56,731
 

Laboratory R&D & Quality Control

 
 
65,387
 
 
 
46,319
 

Total Operating Expenses

 
 
281,485
 
 
 
167,307
 

Net Operating Profit (Loss) EBITDA

 
 
(199,580)
 
 
 
(12,404)
 

Non Cash Depreciation and Amortization

 
 
(22,380
)
 
 
(14,205
)

Non Cash Stock for Services

 
 
–
 
 
 
 
 

Non Cash Interest on Shareholder Debt

 
 
(24,884
)
 
 
(23,033
)

Non Cash Interest on Secured Notes Payable

 
 
(9,986
)
 
 
(9,057
)

Net Income (Loss)

 
 
(256,830)
 
 
 
(58,699)
 

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnositics Inc.

Quarter Ended April 30th;

 
2020
 
 
2019
 

Balance Sheet

ASSETS

Cash

 
 
317,441
 
 
 
128,706
 

Accounts Receivable

 
 
234,146
 
 
 
137,031
 

Inventory

 
 
120,092
 
 
 
51,337
 

Notes Receivable and Prepaids

 
 
75,000
 
 
 
148,084
 

Current Assets

 
 
746,678
 
 
 
465,157
 

 
 
 
 
 
 
–
 

Fixed Assets

 
 
199,099
 
 
 
150,813
 

Intangible and other Assets

 
 
37,993
 
 
 
32,297
 

Total Assets

 
 
983,771
 
 
 
648,267
 

LIABILITIES

Trade Accounts Payable

 
 
93,374
 
 
 
79,130
 

Bank Credit Cards

 
 
33,357
 
 
 
42,017
 

Capital Lease Obligaitons

 
 
46,792
 
 
 
24,896
 

Current Liabiities

 
 
173,523
 
 
 
146,043
 

Secured Convertible Notes

 
 
1,011,988
 
 
 
936,724
 

Capital Lease Obligations

 
 
139,621
 
 
 
65,769
 

Shareholder Accrued Comp. Payable

 
 
1,221,958
 
 
 
1,221,958
 

Shareholder Debts Payable

 
 
672,428
 
 
 
609,815
 

Long Term Liabilities

 
 
3,045,995
 
 
 
2,834,265
 

Total Liabilities

 
 
3,219,518
 
 
 
2,980,309
 

SHAREHOLDERS EQUITY

Series A Convertible Preferred Stock

 
 
595,000
 
 
 
 
 

Common Stock

 
 
22,653
 
 
 
22,653
 

Paid in Capital

 
 
6,633,784
 
 
 
6,633,784
 

Retained Earnings

 
 
(9,132,495
)
 
 
(8,880,576
)

Net Income

 
 
(354,689
)
 
 
(107,902
)

Total Equity

 
 
(2,235,748)
 
 
 
(2,332,041
)

TOTAL LIABILITES AND EQUITY

 
 
983,771
 
 
 
648,268
 

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnostics, Inc.

 
2020
 

Quarter Ended April 30th;

Statement of Cashflows

Net Loss ended April 30th;

 
 
(256,830)
 

Non Cash Depreciation and Amortization

 
 
22,380
 

Increase in current and other Assets

 
 
(60,866
)

Increase in Current and other Current Liabilities

 
 
68,516
 

Equipment,Patent and other capital Expenditures

 
 
(25,974
)

Net cash used in operations during the Quarter

 
 
(252,775)
 

Cashflows from Financing Activities during the Quarter

Series A Convertible Preferred Stock

 
 
145,000
 

Non Cash Secured Note Interest

 
 
24,884
 

Non Cash Shareholder Note Interest

 
 
9,986
 

Net Cash provided by Financing Activities during the Quarter

 
 
179,870
 

Net Increase (Decrease) in Cash for the quarter ended April 30th 2020

 
 
(72,904)
 

Cash Quarter ended January 31st 2020

 
 
390,345
 

Cash Quarter ended April 30th 2020

 
 
317,441
 

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnostics Inc.

Quarter ended April 30th 2020

 
 
 
 
Par
 
 
Paid
 

Statement of Changes in Shareholders Equity

 
Shares
 
 
Value
 
 
in Capital
 

Balance ended January 31st 2020

 
 
45,880,867
 
 
 
22,652
 
 
 
6,633,784
 

Balance Ended April 30th 2020

 
 
45,880,867
 
 
 
22,652
 
 
 
6,633,784
 

The fully diluted Shares outstanding consists of;

Currently issued shares

 
 
45,880,867
 
 
 
 
 
 
 
 
 

Secured Convertible Notes ($987,104 at $0.05 cents/share)

 
 
19,742,080
 
 
 
 
 
 
 
 
 

Management Stock Options vested at $0.05cents/share

 
 
4,120,000
 
 
 
 
 
 
 
 
 

Fully Diluted Shares Outstanding

 
 
69,742,947
 
 
 
 
 
 
 
 
 

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnostics, Inc.

QII ended April 30th 2020 and QI ended Januray 31st 2020

 
2020
 
 
2020
 

Income Statement

Stem Cell Therapies and Treatments

 
 
82,050
 
 
 
167,750
 

Stem Cell Products

 
 
43,288
 
 
 
54,776
 

Other Services

 
 
3,293
 
 
 
3,395
 

Total Revenues

 
 
128,631
 
 
 
225,921
 

COGS

 
 
46,727
 
 
 
56,328
 

Gross Profit

 
 
81,904
64%
 
 
169,593
75%

SGA Expenses

 
 
79,351
 
 
 
65,030
 

Office Expenses

 
 
9,443
 
 
 
8,571
 

Consulting,Accounting,Legal and Banking Fees

 
 
127,304
 
 
 
74,865
 

Laboratory R&D & Quality Control

 
 
65,387
 
 
 
44,919
 

Total Operating Expenses

 
 
281,485
 
 
 
193,385
 

Net Operating Profit (Loss) EBITDA

 
 
(199,580
)
 
 
(23,792
)

Non Cash Depreciation and Amortization

 
 
(22,380
)
 
 
(19,508
)

Non Cash Stock for Services

 
 
–
 
 
 
–
 

Non Cash Interest on Secured Notes Payable

 
 
(24,884
)
 
 
(9,425
)

Non Cash Interest on Shareholder Debt

 
 
(9,986
)
 
 
(24,678
)

Net Income (Loss)

 
 
(256,830
)
 
 
(77,403
)

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

SOURCE: Vitro Diagnostics, Inc.

ReleaseID: 595126

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Nowadays, every dollar counts and proper budgeting is essential with the rising cost of living. Often, people tend to live above their means or have inadequate savings which leads to debt, and sometimes even bankruptcy. That's where Lola Obamehinti comes in. The 29-year-old entrepreneur helps other millennials get their finances under control so they can live their best life.

(Courtesy: Lola Obamehinti, Photographer: Ian Crumpler)

By day, Lola works in tech in Silicon Valley. At night, she writes finance articles on her personal website and blogs about creative ways to save money. As a side hustle, Lola is a freelance TV Host who is regularly called to talk about travel, finance, and technology.

"Honestly, everyone should have a side hustle. Multiple streams of income is the only way to secure yourself during an economic downturn like the one we're currently experiencing due to COVID-19," Lola says.

As a natural public speaker, Lola is comfortable meeting new people and speaking in front of large audiences. She has visited over 15 countries, frequently posting her picture-perfect travel photos on her Instagram. She enjoys spending time with her family and friends. Overall, she has a fulfilled life. However, Lola's journey has not always been smooth sailing.

"After undergrad, I realized I had over $55,000 in student loan debt – and that was after receiving numerous scholarships and grants. I wanted to continue my education but had made a promise to myself that I would never take out another student loan. So I started researching different ways to supplement my income while lowering my living expenses," the young entrepreneur said.

Lola quickly made a plan to pay off her debt. She started looking for better-paying jobs and soon secured a position that doubled her salary. But instead of upgrading her lifestyle, Lola put the extra income towards her debt. She began investing and saving more money. She also applied for numerous graduate scholarships and was awarded several, which she used to completely pay for the expenses for two master's degrees. Six years after beginning her debt payoff plan, Lola finally paid off all $55,000 of her student loans. She then tackled the $10,000 she had left on her car note and credit cards.

Student loan debt in the U.S. is a full blown crisis with roughly 45 million borrowers owing $1.6 trillion dollars. Unfortunately, even if you file for bankruptcy, student loans are the only type of debt that can't be forgiven. As a result of crushing financial pressure and the inability to keep up with student loan payments, many Americans have turned to credit cards to pay their bills in a timely manner. According to a 2020 research study conducted by personal finance website, WalletHub, the amount of total consumer credit card debt in the U.S. is presently over $1 trillion dollars.

"I still have my credit cards but I no longer use them. If I can't pay for something in cash or with my debit card, I simply don't purchase it. I believe healthy money habits and financial literacy is the key to paying off debt and building wealth. Because even if you're making a six-figure or seven-figure income, you will always end up broke when you're living above your means," Lola says.

As someone who is now completely debt-free, Lola is committed to helping others manage their finances. Through her business, she offers consulting sessions and webinars for her peers to assist them in figuring out their own debt payoff strategy. However, with so many people she knows that are without jobs due to COVID-19, Lola has expanded her business to provide complimentary resume reviews and career coaching.

"During this pandemic, so many individuals are seeking jobs or trying to transition into different careers. I noticed this need and wanted to use my expertise to assist others in securing positions. It's a horrible feeling being laid off and not knowing how you'll be able to pay your bills. In times of economic crisis, debt usually goes into delinquency because other necessities have to be paid. I know what it's like to have so much debt that you feel stressed and overwhelmed, which is exactly why I'm determined to help others also get out of debt."

For more information about Lola Obamehinti and what she does, you can visit her website or Instagram. You can also send her an email at Lola.Obamehinti@gmail.com.

SOURCE: Authority Titans

ReleaseID: 595562

Dermacia Pro Eye Serum and Vitamin C Serum are now available for purchase online

LAS VEGAS, NV / ACCESSWIRE / June 29, 2020 / Scepter Holdings, Inc., (OTC PINK:BRZL) a high-performance consumer goods sales and marketing company, releases Dermacia Pro Eye Serum and Vitamin C Serum available for purchase online through DermaciaPro.com.

Dermacia Pro Eye Serum is formulated to be Allergen Free, Paraben Free, Cruelty Free, support Anti-Aging, Smoothing, Exfoliating and Fragrance Free. To be used daily, in the morning and evening to support healthy skin around the eyes.

Dermacia Pro Vitamin C Serum is formulated to be Allergen Free, Paraben Free, Cruelty Free, support Anti-Aging, Smoothing, Detoxifying and Fragrance Free. To be used daily on the face and neck to support healthy skin.

Scepter markets Dermacia Pro products on its brand website, DermaciaPro.com, and through Amazon.com. The new Dermacia Pro Serums complement Dermacia Pro's Breathable Foundation line.

"We are pleased to introduce Dermacia Pro's Eye Serum and Vitamin C Serum, we believe these products support customers caring for their skin and complement our existing Breathable Foundation line of Dermacia Pro products.", stated Adam Nicosia, Vice President of Sales.

About Scepter Holdings, Inc.

Scepter Holdings, Inc. (the "Company") manages the sales and brand development of high-performance consumer packaged goods. The company seeks to acquire performing brands to add to the company's portfolio of products and brands sold online and through strategic retail relationships. The company has expertise manufacturing, distributing, marketing, and selling online consumer packaged goods and seeks to leverage its expertise to grow additional acquired brands. Scepter Holdings, Inc. was incorporated under the laws of the State of Nevada on January 11, 2007.

For more information, please visit our website: http://scepterbrands.com

Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Scepter Holdings, Inc. filings with the Securities and Exchange Commission, which factors may be incorporated herein by reference. Forward-looking statements may be identified but not limited by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Investors Contact:
775-296-5768
info@scepterbrands.com

SOURCE: Scepter Holdings, Inc.

ReleaseID: 595544

CRANBROOK, BC / ACCESSWIRE / June 29, 2020 / Taiga Gold Corp (CSE:TGC) ("Taiga") has mobilized crews to commence fieldwork on its' 100%-owned SAM project located 15km east of Flin Flon, Manitoba, Saskatchewan and 10km northwest of the past producing Flexar and Birch Lake mines. The 1,000ha property is located within the Amisk Group volcanic belt, and is considered to have significant potential to host both orogenic gold and Volcanogenic Massive Sulphide (VMS) mineralization. The property is contiguous with Cameco and SSR Mining Inc. (formerly Silver Standard Resources Inc.). The entire region is located within the Trans-Hudson Orogen – although well known in geological terms has been significantly under-explored in Saskatchewan.

The current program will consist of geological mapping, prospecting, rock sampling and soil geochemical surveys, focusing on gold targets generated by a comprehensive geological compilation and encouraging results from 2018 fieldwork.

A summary map outlining pertinent features of the property may be found here.

SAM Property History and Geology

The property is dominantly underlain by the Amisk Group Collage which forms a major greenstone belt that hosts gold deposits and the majority of base metal deposits in the Flin Flon – Snow Lake areas. Seven documented mineral occurrences are reported on the property including both orogenic gold and VMS style copper-zinc mineralization.

Historical work includes geologic mapping, trenching, soil surveys, airborne and ground geophysical surveys, and 71 short drill holes (6496m total). The first documented work on the property was in 1952-56 when Hudson Bay Exploration completed 43 drillholes targeting VMS mineralization identified by ground EM survey anomalies. Other drill programs in 1978-80 (Granges), 1985 (SMDC) and 2000 (Aur Resources) focused on both VMS and gold targets. St. Eugene Mining completed a heliborne VTEM geophysical survey in 2011. The property was acquired in 2015 by Eagle Plains Resources and later transferred to Taiga as part of a plan of arrangement completed in April 2018.

Taiga completed fieldwork on the property in 2018 including geological mapping, prospecting, rock sampling and soil geochemical surveys, focusing on targets generated by a comprehensive geological compilation of all existing historic data. Historical drill collar locations were surveyed by GPS and a total of 783 soil samples and 59 rock samples were collected. The property area was expanded by staking in 2020.

Historical trench sampling of the Wolverine Zone reportedly returned 24.61 g/t gold over 1.0m (Saskatchewan Mineral Deposit Index "SMDI" 2226), while Golden Bear trenches reported values ranging from trace quantities to a high of 9.61 g/t gold over 1.55m (SMDI 2558).

Much of the historical work was focused on VMS style mineralization though Taiga management considers the project to hold considerable potential for the presence of structurally controlled gold mineralization, which will be the focus of the upcoming program. Mineralization at the SAM has ben defined over a strike length of 200 m, a width of up to 50 m and has been traced to a depth of 200 m by 19 drill-holes. Gold grades vary with the highest grades associated with sections that contain significant sphalerite. Highlights from historic SAM zone drilling include:

DDH #

Depth (m)

Width(m)

Au(g/t)

Cu(%)

Zn(%)

SAM 68-80

45-47.1

2.1

2.56

3.26

0.18

SAM 70-80

28-29.6

1.6

1.65

4.48

0.24

SAM 72-80

69.3-71.7

2.5

1.85

5.52

0.33

Mineralization is open to depth and limited drill testing of the prospective conductive trend west and east of the SAM zone intersected low grade sulphide mineralization.

Management cautions that past results or discoveries on proximate land are not necessarily indicative of the results that may be achieved on the subject properties. The technical information presented above is repeated for historical reference only and cannot be relied upon as the Company's QP, as defined under NI-43-101 has not prepared nor verified the historical information. All drill intercepts are drill indicated lengths. Insufficient technical information exists to demonstrate the true widths of these intersections. All of the technical information is derived from public documents available through the Saskatchewan Government Ministry of the Economy.

Project supervision will be provided by TerraLogic Exploration Inc. of Cranbrook, BC under the supervision of Jarrod Brown, P.Geo. Technical information in this news release has been reviewed and approved by C.C. Downie, P.Geo., a director and officer of Taiga Gold Corp., hereby identified as the "Qualified Person" under N.I. 43-101.

About Taiga Gold Corp

Taiga Gold Corp was created through a plan of arrangement with Eagle Plains Resources Ltd. and owns 5 projects targeting gold in the area near the Seabee Gold Operation, owned and operated by SSR Mining. Taiga's flagship "Fisher" property is currently being explored by SSR Mining under option from Taiga.

Taiga's objective is to focus on the exploration and development of its gold projects located adjacent to the Seabee Gold Operation and along the Tabbernor Fault structure in eastern Saskatchewan, a highly-prospective mining jurisdiction which was recently recognized by the Fraser Institute as one of the highest-rated jurisdictions in the world in terms of Investment Attractiveness. Throughout the exploration and development process, our mission is to help maintain prosperous communities by exploring for and discovering resource opportunities while building lasting relationships through honest and respectful business practices.

On behalf of the Board of Directors

"Tim J. Termuende"
President and CEO

For further information on TGC, please contact Mike Labach at
1 866 HUNT ORE (486 8673)
Email: info@taigagold.com or visit our website at http://taigagold.com

Cautionary Note Regarding Forward-Looking Statements

Neither the CSE nor any other regulatory body has reviewed or approved the contents of this news release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming financings, work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

SOURCE: Taiga Gold Corp.

ReleaseID: 595285

DESTIN, FL / ACCESSWIRE / June 29, 2020 / Duke Mountain Resources Inc. (OTC Pink:DKMR) has announced plans for Xtreme Fighting Championships ("XFC") to continue it's grass roots strategy on a global stage by producing the XFC Tryouts in late 3rd quarter 2020. Many careers have been launched through the XFC Tryouts, including mainstream household names in the Mixed Martial Arts communities. The opportunity to compete in the XFC Hexagon has attracted high level athletes from around the world.

XFC President Myron Molotky explained "Ultimately, world class performance is the only roadmap to fight inside the Hexagon. When we stage XFC 43 in 4th quarter 2020, our roster will mirror past levels to include 185-200 warriors representing 35+ countries. These XFC Tryouts provide opportunity for rising stars on the highest platform provided by our broadcast partners. We believe that the greatest fighters in our sport have not yet been discovered, and we strive to provide the fans with exactly what they expect from the XFC: epic battles and nonstop action, the highest level of production and entertainment, and without question, the introduction to the Next Generation of Champions."

The previously announced first event (United States-Midwest) will be hosted by Team SFS-Scorpion Fighting System in Brighton, Michigan. SFS Founder and owner James David Gray ex-pressed his enthusiasm for the opportunity "Scorpion Fighting System is honored to have been selected to host the Midwest tryouts for XFC. XFC has a long history of creating opportunities for rising stars, and we firmly believe this partnership will enable our world class athletes in the Midwest to earn the right to compete inside the Hexagon. SFS will enter it's top professionals in the XFC Tryouts and we are eager to see the talent that arrives from around the country for this great opportunity."

XFC will return to Brazil in September with a highly anticipated explosive tryout in Sao Paulo at the globally renowned combat team gym Chute Boxe, led by Diego Lima. Chute Boxe has been a core partner with XFC with many of it's athletes competing on past XFC rosters. Considering the widespread talent throughout Brazil, expectations are high to continue building the XFC roster with fan favorites throughout Latin America.

XFC Matchmaker Eduardo Duarte is thrilled "The origins of MMA are traced back to Brazil, and we believe that the best young talent in Latin America will be at these tryouts. The past tryouts in Minas Gerais and Sao Paulo have produced extraordinary talent for our roster. The difficult part will be offering only two hundred applications for this first event. We expect to have a 2nd XFC Tryout in Brazil in Rio de Janeiro as well."

The third confirmed location will provide representation for the United States Southeast region. Former XFC World Champion and X Brand Ambassador Junior Assuncao will host the XFC Try-outs in Atlanta at Ascension Mixed Martial Arts. The Assuncao brothers (Junior, Freddy and Raphael) are considered a first family of MMA, with experience fighting in the three top MMA organizations in the world (XFC, UFC and Bellator). Junior Assuncao also expressed his very enthusiastic support for the return of XFC "I have always been a big supporter of the XFC and look forward to being a part of the relaunch of this global brand. Ascention MMA recently expanded and remodeled so we look forward to hosting the XFC Tryouts for the USA Southeast region"

XFC is finalizing the tryout schedule for 2020 to include two in Europe (East and West), three in Latin America (Brazil, Mexico and Argentina), as well as two more in the United States (USA West and USA Northeast).

Tryout hopefuls will be directed to submit their applications starting July 20, 2020 on the XFC Website: XFCMMA.net in the Next Generation link.

XFC has a new website at XFCMMA.net launching July 6, 2020. News will also be announced on our social media channels, such as our 440,000 fans on Facebook https://www.facebook.com/OfficialXFC/ , Instagram, Twitter and the robust XFC-XFC International YouTube channel.

About the Company

Duke Mountain Resources Inc. (OTC Pink:DKMR) became a primary investor in the sports enter-tainment market of mixed martial arts. As the lead investor of Xtreme Fighting Championships, Inc. ("XFC"), DKMR became XFC and is a premier international mixed martial arts ("MMA") organization with offices throughout the United States and South America. The Xtreme Fighting Championships (XFC) is the only publicly traded independent mixed martial arts (MMA) organization in the world. XFC has partnered with some of the largest open television broadcasters in Latin America – Rede TV! as well as HBO, ESPN, Esportes Interativo, Terra TV (the largest internet portal in the world), and UOL – the largest internet portal in Latin America, and premium cable & satellite television network. New broadcast partners in the USA will be announced in the coming weeks. The XFC has had over 185 exclusively signed fighters, representing over 35+ countries worldwide with even more growth expected. Boasting the signing of The Next Generation of Male & Female Superstars, the XFC is known for entertaining fans with the most action packed MMA events on television and stadium venues. The Next Generation of MMA.

Steve A. Smith Jr.
www.XFCMMA.net
(949) 290-4914
Steve@XFCHub.com

SOURCE: Duke Mountain Resources, Inc.

ReleaseID: 595523